![Richard E. T. Smith](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard E. T. Smith
Keine laufenden Positionen mehr
Ursprung des Netzwerks ersten Grades von Richard E. T. Smith
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Pharmasset, Inc.
![]() Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ.
6
| Subsidiary | Pharmaceuticals: Other | 6 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Richard E. T. Smith
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
EMISPHERE TECHNOLOGIES, INC. | Pharmaceuticals: Major | General Counsel | |
GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal | |
REGENERON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | General Counsel Director of Finance/CFO | |
NPS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Medical Specialties | Corporate Officer/Principal | |
CollaGenex Pharmaceuticals, Inc.
![]() CollaGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CollaGenex Pharmaceuticals, Inc. develops and markets innovative medical therapies to the dental and dermatology market. The company was founded in 1992 and is headquartered in Newtown, PA. | Pharmaceuticals: Major | General Counsel | |
BIOMARIN PHARMACEUTICAL INC. | Biotechnology | Chief Executive Officer | |
Cogenics Icoria, Inc.
![]() Cogenics Icoria, Inc. Miscellaneous Commercial ServicesCommercial Services Cogenics Icoria, Inc. provides medical research services. The firm offers genomics and proteomics-related research instruments, consumables, data, including databases, software & other research-oriented products. Icoria offers gene expression analysis and other related services. Its tissue informatics software performs tissue analysis for toxicology studies of early-stage drug candidates and other purposes. The firm also provides biomarkers to develop diagnostics and therapies for liver injuries, metabolic conditions & cancer. The company is headquartered in Research Triangle Park, NC. | Miscellaneous Commercial Services | Director/Board Member | |
CHIASMA, INC. | Pharmaceuticals: Major | Chairman | |
OMRIX Biopharmaceuticals, Inc.
![]() OMRIX Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ. | Pharmaceuticals: Major | Chairman | |
ARBUTUS BIOPHARMA CORPORATION | Pharmaceuticals: Major | Director/Board Member | |
SHIRE | Pharmaceuticals: Major | General Counsel | |
VIRIOS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Arbutus Biopharma, Inc.
![]() Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Biotechnology | Director/Board Member | |
Dartmouth College | College/University | Undergraduate Degree | |
American University | College/University | Undergraduate Degree | |
Campbell University | College/University | Doctorate Degree | |
Miami University | College/University | Doctorate Degree | |
University of California San Diego | College/University | Undergraduate Degree | |
Zymenex A/S
![]() Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Biotechnology | Chairman | |
Dechert LLP
![]() Dechert LLP Miscellaneous Commercial ServicesCommercial Services Dechert LLP provides legal services. It serves the chemical, construction, finance and real estate, energy, insurance, and health sectors. The firm's practice areas include business restructuring and reorganization, commercial litigation, corporate and securities, energy, finance and real estate, financial services, mergers and acquisitions, and private equity. The company was founded in 1875 and is headquartered in Philadelphia, PA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member | |
Glycadia, Inc.
![]() Glycadia, Inc. Pharmaceuticals: MajorHealth Technology Glycadia, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for the prevention and treatment of kidney, eye, cardiovascular, and related diseases resulting from diabetes. The private company is based in Philadelphia, PA, and has subsidiaries in the United States. The company's science is based on recent discoveries concerning the causal role of circulating glycated. Glycadia's experienced R&D team is bringing new scientific discoveries to clinical trials of innovative products for complications of diabetes, including nephropathy, retinopathy, and cardiovascular disease. | Pharmaceuticals: Major | Chairman | |
RxFDP | Founder | ||
HBL - HADASIT BIO-HOLDINGS LTD | Investment Managers | Director/Board Member | |
Pfizer Pharmaceuticals, Inc.
![]() Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Pharmaceuticals, Inc. is an American company that manufactures pharmaceutical products. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Nutrinia Ltd.
![]() Nutrinia Ltd. Pharmaceuticals: MajorHealth Technology Nutrinia Ltd. develops bioactive feed supplements for infant formulas and animal feed. The firm is involved in broad intellectual property protection, industrial processes envelopment, conducting additional clinical trials and obtaining regulatory approval for the supplementation of pre-term and infant formulas with Insulin. The company was founded by Naim Shehadeh in 2003 and is headquartered in Ramat-Gan, Israel. | Pharmaceuticals: Major | Chief Executive Officer | |
GlaxoSmithKline LLC
![]() GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
MIT Center for Biomedical Innovation
![]() MIT Center for Biomedical Innovation Miscellaneous Commercial ServicesCommercial Services MIT Center for Biomedical Innovation improves global health by overcoming obstacles to the development and implementation of biomedical innovation. Its programs include Biomanufacturing Program, Consortium on Adventitious Agent Contamination in Biomanufacturing and New Drug Development Paradigms program. The company was founded by Frank Lennox Douglas in 2005 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member | |
Gladstone Foundation (CA) | Director/Board Member | ||
Global Virus Network
![]() Global Virus Network Miscellaneous Commercial ServicesCommercial Services Global Virus Network conducts research on essential and critical defense against viral diseases. The non-profit company is based in Baltimore, MD. The company was founded by William Walmsley Hall and Robert C. Gallo. | Miscellaneous Commercial Services | Director/Board Member | |
Scientific Management Review Board | Director/Board Member | ||
The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin | |
Rutgers Law School | College/University | Graduate Degree | |
Drug Innovation Ventures At Emory LLC | Chief Tech/Sci/R&D Officer | ||
Roivant Sciences GmbH
![]() Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Roivant Sciences, Inc.
![]() Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Enzyvant, Inc.
![]() Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Pharmaceuticals: Major | Chief Executive Officer | |
TERNS PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
Antios Therapeutics, Inc.
![]() Antios Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Antios Therapeutics, Inc. operates as a biopharmaceutical company devoted to developing therapies for viral diseases. The company was founded by Abel De La Rosa, Doug Mayers and Idean Marvasty on October 30, 2018 and is headquartered in Atlanta, GA. | Pharmaceuticals: Major | Founder | |
PASSAGE BIO, INC. | Biotechnology | Chief Operating Officer | |
Altavant Sciences, Inc.
![]() Altavant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Altavant Sciences, Inc. is a clinical stage biopharmaceutical company, which provides therapies that treat respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH). The company is headquartered in Cary, NC. | Pharmaceuticals: Major | Chief Executive Officer | |
Enzyvant Therapeutics GmbH
![]() Enzyvant Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Enzyvant Therapeutics GmbH is a Swiss biotechnology company that focuses on developing treatments for rare diseases. The company is based in Basel, Switzerland. William T. Symonds has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Chief Executive Officer | |
CHEMOMAB THERAPEUTICS LTD. | Biotechnology | Director/Board Member |
Statistik
International
Vereinigte Staaten | 41 |
Israel | 5 |
Schweiz | 3 |
Vereinigtes Königreich | 2 |
Irland | 2 |
Sektoral
Health Technology | 32 |
Commercial Services | 8 |
Consumer Services | 8 |
Finance | 2 |
Operativ
Director/Board Member | 44 |
Chairman | 19 |
Corporate Officer/Principal | 14 |
Chief Executive Officer | 10 |
General Counsel | 10 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
G. Steven Burrill | 44 |
Fredric D. Price | 16 |
Paul F. Lubetkin | 11 |
William T. Symonds | 11 |
Jill Quigley | 11 |
Abel de la Rosa | 8 |
- Börse
- Insiders
- Richard E. T. Smith
- Unternehmensverbindungen